Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature

Dasatinib is an oral second-generation multitarget tyrosine-kinase inhibitor (TKI) that is efficacious in treating imatinib-resistant chronic myeloid leukemia (CML) or intolerant cases. Noncutaneous adverse effects with dasatinib are well known in the literature, most commonly cytopenias and fluid r...

Descripción completa

Detalles Bibliográficos
Autores principales: Alharbi, Bader, Alamri, Samer, Mahdi, Ahmed, Marghalani, Siham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077655/
https://www.ncbi.nlm.nih.gov/pubmed/30112222
http://dx.doi.org/10.1155/2018/4062431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077655/
https://www.ncbi.nlm.nih.gov/pubmed/30112222
http://dx.doi.org/10.1155/2018/4062431

Ejemplares similares